Compare Amgen, Inc. (AMGN) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Conagra Brands Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Conagra Brands Inc trades at $13.87 (market cap $6.62B). The key difference: Amgen, Inc. is far larger — about 29.6× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (10.12%). Which is the better fit depends on your goals.
| AMGN | CAG | |
|---|---|---|
Market Cap | $196.12B | $6.62B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $20.02 |
52-Week Low | $271.18 | $12.58 |
Enterprise Value | $241.41B | $13.89B |
Dividend Yield | 2.77% | 10.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Conagra Brands (CAG) trades at $13.83, up 3.52% today but remains near its 52-week lows with a bearish technical outlook. The stock shows mixed fundamentals with a negative net income margin of -0.39% despite recent revenue stabilization around $11.6B. Analyst sentiment is cautious with 62.5% hold ratings, while recent news highlights concerns about dividend sustainability given the company's 10%+ yield and elevated debt levels.
CAG presents a high-risk opportunity with its deeply discounted valuation (P/E 10.06, P/B 0.81) and substantial dividend yield, but faces significant headwinds including declining earnings, high leverage, and competitive pressures in the consumer staples sector. The upcoming Q2 2026 earnings report on July 15 will be critical for confirming operational turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
